Investor contact
For investor related questions, please email
investors@aclaristx.com
Media contact
& resources »

Press Releases

Press Releases

November 16, 2020
Aclaris Therapeutics to Participate in the Evercore ISI 3rd Annual HealthCONx Conference
November 4, 2020
Aclaris Therapeutics Reports Third Quarter 2020 Financial Results and Provides a Corporate Update
October 20, 2020
Aclaris Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of ATI-1777, an Investigational Topical “Soft” JAK 1/3 Inhibitor, for the Treatment of Moderate to Severe Atopic Dermatitis
September 1, 2020
Aclaris Therapeutics to Present at Upcoming Investor Conferences
August 7, 2020
Aclaris Therapeutics Reports Second Quarter 2020 Financial Results and Provides R&D and Business Highlights
July 7, 2020
Aclaris Therapeutics Submits Investigational New Drug Application for ATI-1777, a Topical “Soft” JAK1/3 Inhibitor, for the Treatment of Moderate to Severe Atopic Dermatitis
June 17, 2020
Aclaris Therapeutics Supports Investigator-Initiated Clinical Trial of ATI-450 for Cytokine Release Syndrome in Hospitalized Patients with COVID-19
June 3, 2020
Aclaris Therapeutics Announces Publication of an Abstract of the Phase 1 Clinical Trial Results for ATI-450, an Investigational Compound, at the EULAR 2020 E-Congress
May 26, 2020
Aclaris Therapeutics to Present at the Jefferies Virtual Healthcare Conference
May 7, 2020
Aclaris Therapeutics Reports First Quarter 2020 Financial Results and Provides R&D and Business Highlights
March 31, 2020
Aclaris Therapeutics Secures $11 Million Term Loan Facility
February 25, 2020
Aclaris Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides R&D and Business Highlights
February 19, 2020
Aclaris Therapeutics to Announce Fourth Quarter and Full Year 2019 Financial Results on February 25, 2020
February 10, 2020
Aclaris Therapeutics to Present at the SVB Leerink 9th Annual Global Healthcare Conference
January 9, 2020
Aclaris Therapeutics Announces Positive Results From Phase 1 Single and Multiple Ascending Dose Trial of ATI-450, an Investigational Oral MK2 Inhibitor
January 8, 2020
Aclaris Therapeutics Announces Appointment of Vincent Milano to Board of Directors
Load More »